These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 29784736)

  • 1. Targeted Therapy for Patients With Metastatic Non-Small Cell Lung Cancer.
    Reckamp KL
    J Natl Compr Canc Netw; 2018 May; 16(5S):601-604. PubMed ID: 29784736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.
    Ettinger DS; Aisner DL; Wood DE; Akerley W; Bauman J; Chang JY; Chirieac LR; D'Amico TA; Dilling TJ; Dobelbower M; Govindan R; Gubens MA; Hennon M; Horn L; Lackner RP; Lanuti M; Leal TA; Lilenbaum R; Lin J; Loo BW; Martins R; Otterson GA; Patel SP; Reckamp K; Riely GJ; Schild SE; Shapiro TA; Stevenson J; Swanson SJ; Tauer K; Yang SC; Gregory K; Hughes M
    J Natl Compr Canc Netw; 2018 Jul; 16(7):807-821. PubMed ID: 30006423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
    Hanna N; Johnson D; Temin S; Baker S; Brahmer J; Ellis PM; Giaccone G; Hesketh PJ; Jaiyesimi I; Leighl NB; Riely GJ; Schiller JH; Schneider BJ; Smith TJ; Tashbar J; Biermann WA; Masters G
    J Clin Oncol; 2017 Oct; 35(30):3484-3515. PubMed ID: 28806116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
    Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
    Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.
    Arbour KC; Riely GJ
    JAMA; 2019 Aug; 322(8):764-774. PubMed ID: 31454018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario.
    Addeo A; Tabbò F; Robinson T; Buffoni L; Novello S
    Crit Rev Oncol Hematol; 2018 Feb; 122():150-156. PubMed ID: 29458783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Targeted therapies in non-small cell lung cancer in 2014].
    Leduc C; Besse B
    Rev Mal Respir; 2015 Feb; 32(2):182-92. PubMed ID: 25704901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized therapy for lung cancer: striking a moving target.
    Pakkala S; Ramalingam SS
    JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
    Govindan R; Mandrekar SJ; Gerber DE; Oxnard GR; Dahlberg SE; Chaft J; Malik S; Mooney M; Abrams JS; Jänne PA; Gandara DR; Ramalingam SS; Vokes EE
    Clin Cancer Res; 2015 Dec; 21(24):5439-44. PubMed ID: 26672084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alectinib shows CNS efficacy in ALK-positive NSCLC.
    Gourd E
    Lancet Oncol; 2018 Oct; 19(10):e520. PubMed ID: 30245054
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
    Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
    J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted/emerging therapies for metastatic non-small cell lung cancer.
    Horn L
    J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):676-8. PubMed ID: 25995428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
    Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving Selection Criteria for ALK Inhibitor Therapy in Non-Small Cell Lung Cancer: A Pooled-Data Analysis on Diagnostic Operating Characteristics of Immunohistochemistry.
    Jiang L; Yang H; He P; Liang W; Zhang J; Li J; Liu Y; He J
    Am J Surg Pathol; 2016 May; 40(5):697-703. PubMed ID: 26825369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.
    Couraud S; Barlesi F; Fontaine-Deraluelle C; Debieuvre D; Merlio JP; Moreau L; Beau-Faller M; Veillon R; Mosser J; Al Freijat F; Bringuier PP; Léna H; Ouafik L; Westeel V; Morel A; Audigier-Valette C; Missy P; Langlais A; Morin F; Souquet PJ; Planchard D;
    Eur J Cancer; 2019 Jul; 116():86-97. PubMed ID: 31181537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE; Gandhi L; Costa DB
    Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
    Hanna NH; Robinson AG; Temin S; Baker S; Brahmer JR; Ellis PM; Gaspar LE; Haddad RY; Hesketh PJ; Jain D; Jaiyesimi I; Johnson DH; Leighl NB; Moffitt PR; Phillips T; Riely GJ; Rosell R; Schiller JH; Schneider BJ; Singh N; Spigel DR; Tashbar J; Masters G
    J Clin Oncol; 2021 Mar; 39(9):1040-1091. PubMed ID: 33591844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).
    Golding B; Luu A; Jones R; Viloria-Petit AM
    Mol Cancer; 2018 Feb; 17(1):52. PubMed ID: 29455675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.